2160.T) disclosed today that Gyre Therapeutics, its subsidiary, expects to generate approximately ¥40">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from GNI Group Ltd. was processed by Pulse News Wire on March 13, 2026. It represents a primary source document for Japanese M&A sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Forecasts $400M-$632M Revenue Over Five Years for F351 Treatment | Pulse News Wire

TOKYO, Mar 13 (Pulse News Wire) – GNI Group Ltd. (2160.T) disclosed today that Gyre Therapeutics, its subsidiary, expects to generate approximately ¥40 billion to ¥632 billion in revenue over the next

View all 2160.T disclosures →

Share this disclosure: Share on X Share on LinkedIn